We identified the ApoB:ApoA1 ratio as a potential predictive biomarker of increased CVD risk in patients, who shared a serum metabolomic profile with adult SLE patients with sub-clinical atherosclerosis and a T-cell phenotype with T-cells isolated from human atherosclerotic plaque. Here, APOA1 is linked to systemic lupus erythematosus.